Neurimmune enters into a collaboration and license agreement with AstraZeneca to develop and commercialize NI006

ZURICH, Jan. 7, 2022 /PRNewswire/ — Neurimmune AG today announced that it has entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca’s Rare Disease group, to develop NI006, an investigational human monoclonal antibody specifically targeting…